Guillermo Garcia-Manero, MD, highlights the ASCERTAIN trial in his opening thoughts surrounding MDS in this ASH 2022 post-conference perspective.
ASH 2022 Post Conference Perspectives: Evolutions in the Treatment of Myelodysplastic Syndromes (MDS)
Dr Garcia-Manero discusses the effects of TP53 mutation in patients with MDS.
Treatment strategies for patients with lower-risk MDS are examined.
In his closing thoughts, Dr Garcia-Manero provides an overview of the treatment management approach for patients with MDS.
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease
3
Experts, Patients Highlight Barriers to Arthritis Care Amid World Arthritis Day Observance
4
Medical School Diversity Declines Following Affirmative Action Repeal
5
